Plasma hydroxy-metronidazole/ metronidazole ratio in hepatitis C virus-induced liver disease

Autor: Sergio Mendonça, H. Piovesan, José Pedrazzoli, S.A. Calafatti, M.F. Degger, C.M.F. da Silva, N.M. Cassiano, M. A. M. Marchioretto, C. Ecclissato, Marcelo Lima Ribeiro, G. Bernasconi
Jazyk: angličtina
Rok vydání: 2005
Předmět:
Liver Cirrhosis
Male
Cirrhosis
Physiology
Cytochrome P450
Hepacivirus
medicine.disease_cause
Biochemistry
Gastroenterology
Polymerase Chain Reaction
Severity of Illness Index
law.invention
Liver disease
Anti-Infective Agents
Liver Function Tests
law
General Pharmacology
Toxicology and Pharmaceutics
lcsh:QH301-705.5
Polymerase chain reaction
Chromatography
High Pressure Liquid
lcsh:R5-920
General Neuroscience
General Medicine
Middle Aged
Viral Load
Hepatitis C
Female
medicine.symptom
lcsh:Medicine (General)
medicine.drug
Adult
medicine.medical_specialty
Genotype
Hepatitis C virus
Immunology
Biophysics
Asymptomatic
Liver function
Internal medicine
Metronidazole
HCV status
medicine
Humans
business.industry
Cell Biology
Hepatitis C
Chronic
medicine.disease
lcsh:Biology (General)
Case-Control Studies
business
Biomarkers
Zdroj: Brazilian Journal of Medical and Biological Research, Vol 38, Iss 3, Pp 437-444 (2005)
Brazilian Journal of Medical and Biological Research v.38 n.3 2005
Brazilian Journal of Medical and Biological Research
Associação Brasileira de Divulgação Científica (ABDC)
instacron:ABDC
Brazilian Journal of Medical and Biological Research, Volume: 38, Issue: 3, Pages: 437-444, Published: MAR 2005
Popis: It has been suggested that the measurement of metronidazole clearance is a sensitive method for evaluating liver function. The aim of this study was to evaluate the usefulness of plasma hydroxy-metronidazole/metronidazole ratios as indicators of dynamic liver function to detect changes resulting from the various forms of chronic hepatitis C virus (HCV) infection. A total of 139 individuals were studied: 14 healthy volunteers, 22 healthy, asymptomatic, consecutive anti-HCV-positive HCV-RNA negative subjects, 81 patients with chronic hepatitis C (49 with moderate/severe chronic hepatitis and 34 with mild hepatitis), and 20 patients with cirrhosis of the liver. HCV status was determined by the polymerase chain reaction. Plasma concentrations of metronidazole and its hydroxy-metabolite were measured by reverse-phase high-performance liquid chromatography with ultraviolet detection in a blood sample collected 10 min after the end of a metronidazole infusion. Anti-HCV-positive HCV-RNA-negative individuals demonstrated a significantly reduced capacity to metabolize intravenously infused metronidazole compared to healthy individuals (0.0478 +/- 0.0044 vs 0.0742 +/- 0.0232). Liver cirrhosis patients also had a reduced plasma hydroxy-metronidazole/metronidazole ratio when compared to the other groups of anti-HCV-positive individuals (0.0300 +/- 0.0032 vs 0.0438 +/- 0.0027 (moderate/severe chronic hepatitis) vs 0.0455 +/- 0.0026 (mild chronic hepatitis) and vs 0.0478 +/- 0.0044 (anti-HCV-positive, HCV-RNA-negative individuals)). These results suggest an impairment of the metronidazole metabolizing system induced by HCV infection that lasts after viral clearance. In those patients with chronic hepatitis C, this impairment is paralleled by progression of the disease to liver cirrhosis.
Databáze: OpenAIRE
Externí odkaz: